Approach to MPN Symptom Assessment

Holly Geyer, Ruben A. Mesa

Research output: Contribution to journalArticle

Abstract

Purpose of Review: Myeloproliferative neoplasms (MPNs) are recognized for their debilitating symptom burdens. The purpose of this review is to understand the complexity of the MPN symptom burden and identify how validated MPN Patient Reported Outcome (PRO) tools may be integrated into clinical practice to assess the MPN symptom burden. Recent Findings: Significant heterogeneity exists both within and between MPN subtypes. Surrogates of disease burden such as risk scores and MPN chronicity often fail to correlate with symptomatic burden. Validated MPN PROs allow for precise and rapid assessment of the MPN symptom burden in clinical and trial settings. Their growing use among investigators has resulted in improved understanding of how the MPN disease burden and overall patient experience is impacted by novel and traditional therapies. Summary: PRO tools are an integral part of National Comprehensive Cancer Center (NCCN) guidelines for MPN treatment and should be regularly employed in disease burden assessment.

Original languageEnglish (US)
Pages (from-to)1-8
Number of pages8
JournalCurrent Hematologic Malignancy Reports
DOIs
StateAccepted/In press - Sep 23 2017

Fingerprint

Symptom Assessment
Neoplasms
Research Personnel
Clinical Trials
Guidelines

Keywords

  • Essential thrombocythemia
  • MPN-SAF
  • Myelofibrosis
  • Myeloproliferative neoplasm
  • Polycythemia vera
  • Symptom

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Approach to MPN Symptom Assessment. / Geyer, Holly; Mesa, Ruben A.

In: Current Hematologic Malignancy Reports, 23.09.2017, p. 1-8.

Research output: Contribution to journalArticle

Geyer, Holly ; Mesa, Ruben A. / Approach to MPN Symptom Assessment. In: Current Hematologic Malignancy Reports. 2017 ; pp. 1-8.
@article{6c56cf75e71f4fc99a20179dd22a3731,
title = "Approach to MPN Symptom Assessment",
abstract = "Purpose of Review: Myeloproliferative neoplasms (MPNs) are recognized for their debilitating symptom burdens. The purpose of this review is to understand the complexity of the MPN symptom burden and identify how validated MPN Patient Reported Outcome (PRO) tools may be integrated into clinical practice to assess the MPN symptom burden. Recent Findings: Significant heterogeneity exists both within and between MPN subtypes. Surrogates of disease burden such as risk scores and MPN chronicity often fail to correlate with symptomatic burden. Validated MPN PROs allow for precise and rapid assessment of the MPN symptom burden in clinical and trial settings. Their growing use among investigators has resulted in improved understanding of how the MPN disease burden and overall patient experience is impacted by novel and traditional therapies. Summary: PRO tools are an integral part of National Comprehensive Cancer Center (NCCN) guidelines for MPN treatment and should be regularly employed in disease burden assessment.",
keywords = "Essential thrombocythemia, MPN-SAF, Myelofibrosis, Myeloproliferative neoplasm, Polycythemia vera, Symptom",
author = "Holly Geyer and Mesa, {Ruben A.}",
year = "2017",
month = "9",
day = "23",
doi = "10.1007/s11899-017-0399-5",
language = "English (US)",
pages = "1--8",
journal = "Current Hematologic Malignancy Reports",
issn = "1558-8211",
publisher = "Springer Science + Business Media",

}

TY - JOUR

T1 - Approach to MPN Symptom Assessment

AU - Geyer, Holly

AU - Mesa, Ruben A.

PY - 2017/9/23

Y1 - 2017/9/23

N2 - Purpose of Review: Myeloproliferative neoplasms (MPNs) are recognized for their debilitating symptom burdens. The purpose of this review is to understand the complexity of the MPN symptom burden and identify how validated MPN Patient Reported Outcome (PRO) tools may be integrated into clinical practice to assess the MPN symptom burden. Recent Findings: Significant heterogeneity exists both within and between MPN subtypes. Surrogates of disease burden such as risk scores and MPN chronicity often fail to correlate with symptomatic burden. Validated MPN PROs allow for precise and rapid assessment of the MPN symptom burden in clinical and trial settings. Their growing use among investigators has resulted in improved understanding of how the MPN disease burden and overall patient experience is impacted by novel and traditional therapies. Summary: PRO tools are an integral part of National Comprehensive Cancer Center (NCCN) guidelines for MPN treatment and should be regularly employed in disease burden assessment.

AB - Purpose of Review: Myeloproliferative neoplasms (MPNs) are recognized for their debilitating symptom burdens. The purpose of this review is to understand the complexity of the MPN symptom burden and identify how validated MPN Patient Reported Outcome (PRO) tools may be integrated into clinical practice to assess the MPN symptom burden. Recent Findings: Significant heterogeneity exists both within and between MPN subtypes. Surrogates of disease burden such as risk scores and MPN chronicity often fail to correlate with symptomatic burden. Validated MPN PROs allow for precise and rapid assessment of the MPN symptom burden in clinical and trial settings. Their growing use among investigators has resulted in improved understanding of how the MPN disease burden and overall patient experience is impacted by novel and traditional therapies. Summary: PRO tools are an integral part of National Comprehensive Cancer Center (NCCN) guidelines for MPN treatment and should be regularly employed in disease burden assessment.

KW - Essential thrombocythemia

KW - MPN-SAF

KW - Myelofibrosis

KW - Myeloproliferative neoplasm

KW - Polycythemia vera

KW - Symptom

UR - http://www.scopus.com/inward/record.url?scp=85029749283&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029749283&partnerID=8YFLogxK

U2 - 10.1007/s11899-017-0399-5

DO - 10.1007/s11899-017-0399-5

M3 - Article

C2 - 28942516

AN - SCOPUS:85029749283

SP - 1

EP - 8

JO - Current Hematologic Malignancy Reports

JF - Current Hematologic Malignancy Reports

SN - 1558-8211

ER -